idiopathic pulmonary fibrosis

BMS scores another phase 2 win for its pulmonary fibrosis drug

Bristol Myers Squibb (BMS) is making significant strides in the field of pulmonary fibrosis treatment, particularly with its lysophosphatidic acid ...